Ken Duncan

6.1k total citations · 2 hit papers
52 papers, 4.7k citations indexed

About

Ken Duncan is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Ken Duncan has authored 52 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Infectious Diseases, 34 papers in Epidemiology and 18 papers in Molecular Biology. Recurrent topics in Ken Duncan's work include Tuberculosis Research and Epidemiology (40 papers), Mycobacterium research and diagnosis (31 papers) and Cancer therapeutics and mechanisms (6 papers). Ken Duncan is often cited by papers focused on Tuberculosis Research and Epidemiology (40 papers), Mycobacterium research and diagnosis (31 papers) and Cancer therapeutics and mechanisms (6 papers). Ken Duncan collaborates with scholars based in United Kingdom, United States and South Africa. Ken Duncan's co-authors include Pauline T. Lukey, Joanna Betts, Ruth A. McAdam, Clifton E. Barry, Douglas B. Young, Paul D. van Helden, Mark D. Perkins, Tanya Parish, Neil G. Stoker and Kiyoshi Kita and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ken Duncan

51 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling

2002 1.1k citations Joanna Betts, Pauline T. Lukey et al. Molecular Microbiology profile →
Hit and lead criteria in drug discovery for infectious diseases of the developing world

2015 431 citations Jeremy N. Burrows, Ken Duncan et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Duncan United Kingdom	31	3.0k	2.4k	1.9k	683	583	52	4.7k
James C. Sacchettini United States	38	3.4k 1.1×	2.4k 1.0×	3.4k 1.8×	1.1k 1.6×	509 0.9×	41	6.4k
Kévin Pethe Singapore	40	2.9k 1.0×	2.3k 1.0×	2.4k 1.3×	519 0.8×	520 0.9×	93	5.4k
Anil Koul Belgium	27	3.1k 1.0×	2.0k 0.8×	2.8k 1.5×	539 0.8×	384 0.7×	40	4.9k
Anne J. Lenaerts United States	42	3.2k 1.1×	2.3k 1.0×	1.9k 1.0×	830 1.2×	703 1.2×	93	5.0k
Kyu Y. Rhee United States	43	2.8k 0.9×	1.9k 0.8×	3.2k 1.7×	250 0.4×	352 0.6×	116	5.4k
Gyanu Lamichhane United States	37	2.5k 0.8×	2.1k 0.9×	1.4k 0.8×	464 0.7×	457 0.8×	93	3.9k
Michael H. Cynamon United States	41	2.9k 1.0×	2.5k 1.0×	1.5k 0.8×	946 1.4×	553 0.9×	132	4.8k
Tanya Parish United States	50	5.0k 1.7×	3.8k 1.6×	4.0k 2.1×	807 1.2×	603 1.0×	195	7.8k
Thomas Dick Singapore	49	5.4k 1.8×	4.4k 1.8×	3.8k 2.0×	942 1.4×	930 1.6×	201	8.5k
Richard A. Slayden United States	37	2.4k 0.8×	1.7k 0.7×	2.3k 1.2×	1.1k 1.6×	327 0.6×	85	4.7k

Countries citing papers authored by Ken Duncan

Since Specialization

Citations

This map shows the geographic impact of Ken Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Duncan more than expected).

Fields of papers citing papers by Ken Duncan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Duncan. The network helps show where Ken Duncan may publish in the future.

Co-authorship network of co-authors of Ken Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Duncan. A scholar is included among the top collaborators of Ken Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Duncan. Ken Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ginsburg, Amy Sarah, Ken Duncan, Keith P. Klugman, & Padmini Srikantiah. (2024). Access to antibiotics for pneumonia and sepsis in LMICs. The Lancet Global Health. 12(12). e1928–e1929. 1 indexed citations

Duncan, Ken, et al.. (2017). Session 1. Social Science Open Access Repository (GESIS – Leibniz Institute for the Social Sciences).

Burrows, Jeremy N., Ken Duncan, Rob Hooft van Huijsduijnen, et al.. (2015). Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery. 14(11). 751–758. 431 indexed citations breakdown →

Cliff, Jacqueline M., Ji‐Sook Lee, Nicholas Constantinou, et al.. (2012). Distinct Phases of Blood Gene Expression Pattern Through Tuberculosis Treatment Reflect Modulation of the Humoral Immune Response. The Journal of Infectious Diseases. 207(1). 18–29. 169 indexed citations

Young, Douglas B., Mark D. Perkins, Ken Duncan, & Clifton E. Barry. (2008). Confronting the scientific obstacles to global control of tuberculosis. Journal of Clinical Investigation. 118(4). 1255–1265. 246 indexed citations

Carroll, Nora M., Pieter Uys, Anneke C. Hesseling, et al.. (2008). Prediction of delayed treatment response in pulmonary tuberculosis: Use of time to positivity values of Bactec cultures. Tuberculosis. 88(6). 624–630. 8 indexed citations

Wall, Michael D., Gavin A.C. Chung, Esperanza Herreros, et al.. (2007). Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth. Bioorganic & Medicinal Chemistry Letters. 17(10). 2740–2744. 19 indexed citations

Villiers, Chantal Babb de, Lize van der Merwe, Nulda Beyers, et al.. (2007). Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis. 87(4). 295–302. 73 indexed citations

Stumpf, Michael P. H., Brian D. Robertson, Ken Duncan, & Douglas Young. (2007). Systems biology and its impact on anti-infective drug development. Birkhäuser Basel eBooks. 64. 1–20. 5 indexed citations

10.

Williams, Kerstin J. & Ken Duncan. (2007). Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB. Current Molecular Medicine. 7(3). 297–307. 30 indexed citations

11.

Mistry, Rohit, Jacqueline M. Cliff, Christopher L. Clayton, et al.. (2007). Gene‐Expression Patterns in Whole Blood Identify Subjects at Risk for Recurrent Tuberculosis. The Journal of Infectious Diseases. 195(3). 357–365. 107 indexed citations

12.

Cliff, Jacqueline M., Rohit Mistry, Christopher L. Clayton, et al.. (2004). Differential Gene Expression Identifies Novel Markers of CD4+ and CD8+ T Cell Activation Following Stimulation by Mycobacterium tuberculosis. The Journal of Immunology. 173(1). 485–493. 22 indexed citations

13.

Kendall, Sharon L., Farahnaz Movahedzadeh, Stuart Rison, et al.. (2004). The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses. Tuberculosis. 84(3-4). 247–255. 114 indexed citations

14.

Duncan, Ken & Clifton E. Barry. (2004). Prospects for new antitubercular drugs. Current Opinion in Microbiology. 7(5). 460–465. 109 indexed citations

15.

Parish, Tanya, et al.. (2003). Gene Replacement in Mycobacteria by Using Incompatible Plasmids. Applied and Environmental Microbiology. 69(1). 517–523. 21 indexed citations

16.

Duncan, Ken. (2003). Progress in TB drug development and what is still needed. Tuberculosis. 83(1-3). 201–207. 70 indexed citations

17.

Betts, Joanna, et al.. (2002). Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Molecular Microbiology. 43(3). 717–731. 1140 indexed citations breakdown →

18.

Fenhalls, Gael, et al.. (2002). Distribution of IFN‐γ, IL‐4 and TNF‐α protein and CD8 T cells producing IL‐12p40 mRNA in human lung tuberculous granulomas. Immunology. 105(3). 325–335. 60 indexed citations

19.

Kremer, Laurent, Lynn G. Dover, Caroline Morehouse, et al.. (2001). Galactan Biosynthesis in Mycobacterium tuberculosis. Journal of Biological Chemistry. 276(28). 26430–26440. 125 indexed citations

20.

Gordon, Stephen V., et al.. (1996). Rapid measurement of antimycobacterial drug activity. Research in Microbiology. 147(1-2). 79–86. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact